Browsing by Author "Ozsaran A."

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Effect of surgical staging on 539 patients with borderline ovarian tumors: A Turkish Gynecologic Oncology Group study
    (2013) Guvenal T.; Dursun P.; Hasdemir P.S.; Hanhan M.; Guven S.; Yetimalar H.; Goksedef B.P.; Sakarya D.K.; Doruk A.; Terek M.C.; Saatli B.; Guzin K.; Corakci A.; Deger E.; Celik H.; Cetin A.; Ozsaran A.; Ozbakkaloglu A.; Kolusari A.; Celik C.; Keles R.; Sagir F.G.; Dilek S.; Uslu T.; Dikmen Y.; Altundag O.; Ayhan A.
    Objective The objectives of this study were to examine demographic and clinicopathologic characteristics and to determine the effects of primary surgery, surgical staging and the extensiveness of staging. Methods In a retrospective Turkish multicenter study, 539 patients, from 14 institutions, with borderline ovarian tumors were investigated. Some of the demographic, clinical and surgical characteristics of the cases were evaluated. The effects of type of surgery, surgical staging; complete or incomplete staging on survival rates were calculated by using Kaplan-Meier method. Results The median age at diagnosis was 40 years (range 15-84) and 71.1% of patients were premenopausal. The most common histologic types were serous and mucinous. Majority of the staged cases were in Stage IA (73.5%). 242 patients underwent conservative surgery. Recurrence rates were significantly higher in conservative surgery group (8.3% vs. 3%). Of all patients in this study, 294 (54.5%) have undergone surgical staging procedures. Of the patients who underwent surgical staging, 228 (77.6%) had comprehensive staging including lymphadenectomy. Appendectomy was performed on 204 (37.8%) of the patients. The median follow-up time was 36 months (range 1-120 months). Five-year survival rate was 100% and median survival time was 120 months. Surgical staging, lymph node sampling or dissection and appendectomy didn't cause any difference on survival. Conclusion Comprehensive surgical staging, lymph node sampling or dissection and appendectomy are not beneficial in borderline ovarian tumors surgical management. © 2013 Elsevier Inc.
  • No Thumbnail Available
    Item
    Multicenter analysis of gestational trophoblastic neoplasia in Turkey
    (Asian Pacific Organization for Cancer Prevention, 2014) Ozalp S.S.; Telli E.; Oge T.; Tulunay G.; Boran N.; Turan T.; Yenen M.; Kurdoglu Z.; Ozler A.; Yuce K.; Ulker V.; Arvas M.; Demirkiran F.; Bese T.; Tokgozoglu N.; Onan A.; Sanci M.; Gokcu M.; Tosun G.; Dikmen Y.; Ozsaran A.; Terek M.C.; Akman L.; Yetimalar H.; Kilic D.S.; Gungor T.; Ozgu E.; Yildiz Y.; Kokcu A.; Kefeli M.; Kuruoglu S.; Yuksel H.; Guvenal T.; Hasdemir P.S.; Ozcelik B.; Serin S.; Dolanbay M.; Arioz D.T.; Tuncer N.; Bozkaya H.; Guven S.; Kulaksiz D.; Varol F.; Yanik A.; Ogurlu G.; Simsek T.; Toptas T.; Dogan S.; Camuzoglu H.; Api M.; Guzin K.; Caliskan E.; Doger E.; Cakmak B.; Ilhan T.T.
    Background: To evaluate the incidence, diagnosis and management of GTN among 28 centers in Turkey. Materials and Methods: A retrospective study was designed to include GTN patients attending 28 centers in the 10-year period between January 2003 and May 2013. Demographical characteristics of the patients, histopathological diagnosis, the International Federation of Gynecology and Obstetrics (FIGO) anatomical and prognostic scores, use of single-agent and multi-agent chemotherapy, surgical interventions and prognosis were evaluated. Results: From 2003-2013, there were 1,173,235 deliveries and 456 GTN cases at the 28 centers. The incidence was calculated to be 0.38 per 1,000 deliveries. According to the evaluated data of 364 patients, the median age at diagnosis was 31 years (range, 15-59 years). A histopathological diagnosis was present for 45.1% of the patients, and invasive mole, choriocarcinoma and PSTTs were diagnosed in 22.3% (n=81), 18.1% (n=66) and 4.7% (n=17) of the patients, respectively. Regarding final prognosis, 352 (96.7%) of the patients had remission, and 7 (1.9%) had persistence, whereas the disease was mortal for 5 (1.4%) of the patients. Conclusions: Because of the differences between countries, it is important to provide national registration systems and special clinics for the accurate diagnosis and treatment of GTN.
  • No Thumbnail Available
    Item
    Investigation of cytotoxic and apoptotic effects of disodium pentaborate decahydrate on ovarian cancer cells and assessment of gene profiling
    (Springer, 2023) Gunel N.S.; Yildirim N.; Ozates N.P.; Oktay L.M.; Bagca B.G.; Sogutlu F.; Ozsaran A.; Korkmaz M.; Biray Avci C.
    After revealing the anti-cancer properties of boron, which is included in the category of essential elements for human health by the World Health Organization, the therapeutic potential of boron compounds has been begun to be evaluated, and its molecular effect mechanisms have still been among the research subjects. In ovarian cancer, mutations or amplifications frequently occur in the PI3K/Akt/mTOR pathway components, and dysregulation of this pathway is shown among the causes of treatment failure. In the present study, it was aimed to investigate the anti-cancer properties of boron-containing DPD in SKOV3 cells, which is an epithelial ovarian cancer model, through PI3K/AKT/mTOR pathway. The cytotoxic activity of DPD in SKOV3 cells was evaluated by WST-1 test, apoptotic effect by Annexin V and JC-1 test. The gene expressions associated with PI3K/AKT/mTOR pathway were determined by real-time qRT-PCR. In SKOV3 cells, the IC50 value of DPD was found to be 6.7 mM, 5.6 mM, and 5.2 mM at 24th, 48th and 72nd hour, respectively. Compared with the untreated control group, DPD treatment was found to induce apoptosis 2.6-fold and increase mitochondrial membrane depolarization 4.5-fold. DPD treatment was found to downregulate PIK3CA, PIK3CG, AKT2, IGF1, IRS1, MAPK3, HIF-1, VEGFC, CAB39, CAB39L, STRADB, PRKAB2, PRKAG3, TELO2, RICTOR, MLST8, and EIF4B genes and upregulate TP53, GSK3B, FKBP8, TSC2, ULK1, and ULK2 genes. These results draw attention to the therapeutic potential of DPD, which is frequently exposed in daily life, in epithelial ovarian cancer and show that it can be a candidate compound in combination with chemotherapeutics. © 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.